Lacey David L. 4

What Happened
David L. Lacey, a director of Arcus Biosciences (RCUS), received two awards on 2026-06-11: 5,700 restricted stock units (RSUs) and 16,900 derivative awards (stock option-type award). Both awards are reported at $0.00 per share (total reported value $0) and were filed on Form 4 on 2026-06-12. These were grant/award transactions (compensation), not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-11; Form 4 filed: 2026-06-12 (appears timely).
• Price reported: $0.00 for both awards.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes:
  • F1: The 5,700 RSUs vest in full on the earlier of June 11, 2027 or the next annual meeting; they vest immediately upon a change in control.
  • F2: The 16,900 derivative award will vest in full on the earlier of June 11, 2027 or the next annual meeting and becomes fully vested/exercisable upon a change in control.
• Transaction code: A = Award/Grant.

Context
These awards are director compensation and not an open-market buy or sale; such grants are routine and do not necessarily signal the director’s near-term trading intent. The derivative award appears to be an option-like award that will vest (and, in the case of the option, become exercisable) according to the schedule above or sooner on a change in control.